Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.48 |
| ▸ | PRKCG | P05129 | 2/20 | 0.48 |
| ▸ | PRKCB | P05771 | 2/20 | 0.48 |
| ▸ | PRKCA | P17252 | 2/20 | 0.48 |
| ▸ | PRKCH | P24723 | 2/20 | 0.48 |
| ▸ | PRKCI | P41743 | 2/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.48 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 13/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7674359 | 0.94 | EPHX1 (0.60) | EPHX1ALDH1A1PRKD3PRKCGPRKCB | |
| SCHEMBL28218988 | 0.91 | EPHX1 (0.55) | EPHX1ALDH1A1PRKD3PRKCGPRKCB | |
| SCHEMBL7678863 | 0.91 | EPHX1 (0.60) | EPHX1ALDH1A1PRKD3PRKCGPRKCB | |
| SCHEMBL7764030 | 0.90 | EPHX1 (0.55) | EPHX1ALDH1A1PRKD3PRKCGPRKCB | |
| SCHEMBL7760388 | 0.87 | EPHX1 (0.56) | EPHX1ALDH1A1PRKD3PRKCGPRKCB | |
| SCHEMBL28212337 | 0.83 | EPHX1 (0.47) | EPHX1ALDH1A1PRKD3PRKCGPRKCB | |
| SCHEMBL7764100 | 0.82 | EPHX1 (0.46) | EPHX1ALDH1A1PRKD3PRKCGPRKCB | |
| SCHEMBL7764093 | 0.82 | EPHX1 (0.46) | EPHX1ALDH1A1PRKD3PRKCGPRKCB | |
| SCHEMBL7832019 | 0.82 | ALDH1A1 (0.68) | EPHX1ALDH1A1PRKD3PRKCGPRKCB | |
| SCHEMBL7678940 | 0.81 | EPHX1 (0.62) | EPHX1ALDH1A1PRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277012-A1 | DUPLICATE BEVERAGE | WANG JIE (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118076767-A | Method and formulation for producing an optical metal oxide layer | 默克专利有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023057401-A1 | METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS | MERCK PATENT GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | SAKARIASSEN KJELL STEINAR (IT) | 2016-07-07 | — | — | US | disclosed |
| WO-2015193630-A1 | TREATMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH CARDIOVASCULAR DISEASE AND/OR DIABETES | EVOLVA SA (CH) | 2015-12-23 | — | — | WO | disclosed |
| EP-2934513-A2 | TREATMENT OF CARDIOVASCULAR RISK IN DIABETIC PATIENTS | Evolva SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8952053-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2015-02-10 | — | — | US | disclosed |
| WO-2014106775-A2 | TREATMENT OF CARDIOVASCULAR RISK IN DIABETIC PATIENTS | EVOLVA SA (CH) | 2014-07-10 | — | — | WO | disclosed |
| US-20130253045-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2013-09-26 | — | — | US | disclosed |
| US-8486994-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-2120567-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | Evolva SA (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008089464-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
| EP-1021433-B1 | METHOD FOR PRODUCING NATURAL DIOL-1,3 DERIVATIVES AND CORRESPONDING NATURAL 1,3-DIOXANE DERIVATIVES | PERNOD RICARD (FR) | 2001-11-14 | — | — | EP | disclosed |
| EP-0927176-B1 | 1,3-DIOXANE DERIVATIVES, SYNTHESIS METHOD THEREFOR AND AROMATIC COMPOSITIONS CONTAINING SAME | PERNOD RICARD (FR) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | P2RY12, P2RY13, P2RY6 | EPHX1 129/4885ALDH1A1 447/4885PRKD3 1822/4885 |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | EPHX1 344/4885ALDH1A1 440/4885PRKD3 1249/4885 |
| US-20130253045-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | TBXA2R, PPARG, PPARA | EPHX1 344/4885ALDH1A1 440/4885PRKD3 1249/4885 |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | TBXA2R, PPARG, PPARA | EPHX1 344/4885ALDH1A1 440/4885PRKD3 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.